MetaCap

CytoMed Therapeutics (GDTC) vs Vyome (HIND)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CytoMed Therapeutics (GDTC) has outperformed Vyome (HIND) over the past year, losing 59.8% versus a loss of 75.9%. CytoMed Therapeutics is the larger company by market cap ($9.0 million vs $8.4 million), about 1.1 times the size. CytoMed Therapeutics converts more of its revenue into profit, with a net margin of -1227.1% versus -3209.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GDTC-59.84%HIND-75.90%
+20%-30%-80%
Nov 21, 20251 yearNov 20, 2026
GDTC-81.13%HIND-99.99%
+29%-39%-106%
Apr 10, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GDTC versus HIND key metrics
MetricGDTCHIND
Share price$0.755$1.20
Market cap$9.01M$8.42M
1-day change-2.33%-17.24%
YTD return-43.45%-65.12%
1-year return-59.84%-75.90%
5-year return—-100.00%
P/E ratio (TTM)—0.25
EPS (TTM)$-0.23$4.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$252.26K$319.71K
Revenue growth (YoY)+395.88%+24.43%
Net income (latest FY)$-3.10M$-10.26M
Gross margin—68.43%
Operating margin—-3269.35%
Net margin-1227.07%-3209.75%
52-week high$2.12$5.88
52-week low$0.68$1.20
Distance from 52-week high-64.39%-79.59%
Analyst consensusnonestrong_buy
Avg. price target upside+450.99%+635.83%
Average volume15.69K13.92K
Shares outstanding11.93M7.02M
Employees429
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GDTC has outperformed HIND by 16.1 percentage points over the past year.
  • CytoMed Therapeutics is more profitable, keeping -1227.1 cents of every revenue dollar as net income versus -3209.7 cents for Vyome.
  • CytoMed Therapeutics grew revenue faster in its latest fiscal year (+395.88% vs +24.43%).

About CytoMed Therapeutics

GDTC stock →

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees

About Vyome

HIND stock →

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

GDTC vs HIND FAQ

Which is bigger, CytoMed Therapeutics or Vyome?

CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $9.01M compared with $8.42M for Vyome (HIND).

Which stock has performed better over the past year, GDTC or HIND?

GDTC returned -59.84% over the past 12 months, compared with -75.90% for HIND (price return, excluding dividends). Past performance does not predict future results.

Are CytoMed Therapeutics and Vyome in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons